Sector News

Actavis job-cutting drive hits 400-plus on Long Island

March 18, 2015
Life sciences
New-look Actavis–soon to be Allergan–has been undergoing plenty of changes since it agreed in November to shell out $66 billion for the Botox maker. And as it continues to integrate Allergan’s ops, it’s shaving away at the workforce it inherited from its prior pickup, Forest Labs.
 
Last week, the company updated its Long Island, NY, jobs toll to 412, with the bulk of those in commercial packaging operations. Forty-seven of the job-cutting total are sales staffers who work remotely, according to a New York state WARN notice.
 
Actavis first announced the layoffs back in September, and since then it’s gotten to work trimming Forest’s ranks in other states, too. Last July, it delivered pink slips to 190 workers in Earth City, MO, after deciding to close a facility there. And in December, it said it would cut loose 200 more in Corona, CA, an area that’s been part of a gradual drawdown.
 
What Actavis hasn’t yet said, though, is whether, which and when employees will face the ax as a result of its Allergan tie-up. The deal, which added 11,500 staffers to the 25,000 employees Actavis already had, closed this week after clearing its final regulatory hurdle
 
But word on any forthcoming scale-back could be coming sooner rather than later. The Dublin drugmaker has pledged $1.8 billion in cost savings–the majority of which are due within the next year.
 
By Carly Helfand
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]